Peng Bi, Yan Yuanliang, Xu Zhijie
Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
PeerJ. 2021 Sep 1;9:e12123. doi: 10.7717/peerj.12123. eCollection 2021.
Serving as N6-methyladenosine demethylases, the AlkB family is involved in the tumorigenesis of hepatocellular carcinoma (HCC). However, the molecular profiles and clinical values of the AlkB family in HCC are not well known.
Several bioinformatics tools and experiments were used to identify the immune-related profiles and prognostic values of AlkB family in HCC.
In this study expression levels of ALKBH1/2/3/4/7 were all remarkably increased in HCC tissues when compared with normal tissues. Quantitative PCR (qPCR) and immunohistochemistry were used to validate the expression of AlkB family members in HCC tissues and normal liver tissues. In addition, high expression levels of ALKBH4 were negatively correlated with overall survival (OS) and disease-free survival (DFS) in patients with HCC. Increased ALKBH4 was also associated with pathological stage in HCC patients. The molecular profiles of AlkB family in HCC were mainly associated with peptidyl-serine modification, peptidyl-tyrosine modification, regulation of metal ion transport, etc. Furthermore, tumor-infiltrating immune cell analysis indicated that ALKBH1/2/3/4/5/6/7/8 and FTO were related to the infiltration of different immune cell, such as CD8+ T cells, macrophages, neutrophils, dendritic cells and CD4+ T cells. We also discovered that the methylation levels of ALKBH1/2/4/5/6/8 and FTO were remarkably reduced in HCC tissues.
Collectively, our findings may deepen the understanding of specific molecular profiles of the AlkB family in HCC pathology. In particular, ALKBH4 could serve as a promising prognostic candidate for treating HCC, and these results might potentiate the development of more reliable therapeutic strategies for patients with HCC.
作为N6-甲基腺苷去甲基化酶,AlkB家族参与肝细胞癌(HCC)的肿瘤发生。然而,AlkB家族在HCC中的分子特征和临床价值尚不清楚。
使用多种生物信息学工具和实验来确定AlkB家族在HCC中的免疫相关特征和预后价值。
在本研究中,与正常组织相比,HCC组织中ALKBH1/2/3/4/7的表达水平均显著升高。采用定量PCR(qPCR)和免疫组织化学方法验证AlkB家族成员在HCC组织和正常肝组织中的表达。此外,ALKBH4的高表达水平与HCC患者的总生存期(OS)和无病生存期(DFS)呈负相关。ALKBH4的升高也与HCC患者的病理分期有关。HCC中AlkB家族的分子特征主要与肽基丝氨酸修饰、肽基酪氨酸修饰、金属离子转运调节等有关。此外,肿瘤浸润免疫细胞分析表明,ALKBH1/2/3/4/5/6/7/8和FTO与不同免疫细胞如CD8+T细胞、巨噬细胞、中性粒细胞、树突状细胞和CD4+T细胞的浸润有关。我们还发现,HCC组织中ALKBH1/2/4/5/6/8和FTO的甲基化水平显著降低。
总体而言,我们的研究结果可能会加深对AlkB家族在HCC病理学中特定分子特征的理解。特别是,ALKBH4有望成为治疗HCC预后的候选指标,这些结果可能会促进为HCC患者开发更可靠的治疗策略。